[Relapsed Hodgkin lymphoma with only breast involvement: a rare case report]. / Rechute mammaire isolée d'un lymphome de Hodgkin: à propos d'un cas rare.

Relapsed Hodgkin lymphoma with only breast involvement is rare. There is no specific clinical presentation. It can mimic another breast cancer or inflammatory disease. The histological profile is often misleading in the pauci-cellular forms where the inflammatory component predominates. We report a case of an 18-year-old female patient treated for mixed-cell Hodgkin lymphoma who was admitted 6 months after complete remission for a left breast inflammatory nodule. The first assessment showed breast abscess. As there was not a good outcome despite adapted antibiotic, more investigations were added and showed a relapsed Hodgkin lymphoma with only breast involvement. The patient is currently receiving a 4th therapeutic line regimen of chemotherapy. Breast Hodgkin lymphoma´s prognosis is poor in most cases reported in the literature. Therapeutic advances (targeted therapy) can improve patient outcomes.

[IgD multiple myeloma mimicking free light chain myeloma complicated by factor X deficiency: a case report]. / Myélome multiple à IgD mimant un myélome à chaines légères libres et compliqué de déficit en facteur X: à propos d'un cas.

IgD myeloma is an extremely rare haemopathy with severe clinical presentation. It can be confused with non-secretory or free light chain myeloma. We here report the case of a 72-year old female patient presenting with bone pain and diffuse ecchymosis and deterioration of her general condition. Laboratory tests showed monoclonal gammopathy associated with severe acute renal failure and low total protein (TP) (48%) with factor X deficiency. Etiological assessment confirmed the diagnosis of IgD lambda myeloma stage IIIb, according to Durie and Salmon, International Staging System (ISS) score III unfavorable cytogenetics. Patient's outcome was favorable after treatment with proteasome inhibitor, anti-CD 38 and corticosteroid therapy. Adequate treatment of IgD myeloma, using new therapeutic approaches and hematopoietic stem cell autotransplantation, can improve the prognosis.